| Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi |
2023-03-16 |
| Teitur Trophics–Optimum Strategic Communications: public relations, 202303 service existent by Optimum |
2023-03-14 |
| UCB–Cancer Research UK: antibody cancer drugs, 202303– collab clinical development of UCB6114 + UCB4594 |
2023-03-09 |
| AstraZeneca–Personalis: precision oncology, 202303– collab continuation use of NeXT Personal assay for clinical reserach + drug development |
2023-03-07 |
| Antiverse–SEVERAL: investment, 202303 financing round $3m from existing + new investors |
2023-03-01 |
| Five Alarm Bio–Acceleris: investment, 202302 seed financing round totalling >£500k incl angel investors with support from KPMG Acceleris |
2023-02-27 |
| Five Alarm Bio–Cambridge Angels: investment, 202302 seed financing round totalling >£500k incl investor Cambridge Angels |
2023-02-27 |
| Five Alarm Bio–Meltwind: investment, 202302 seed financing round totalling >£500k incl investor Meltwind |
2023-02-27 |
| Five Alarm Bio–o2h: investment, 202302 seed financing round totalling >£500k incl investor o2h Ventures |
2023-02-27 |
| Five Alarm Bio–SEVERAL: investment, 202302 seed financing round >£500k |
2023-02-27 |
| Five Alarm Bio–SyndicateRoom: investment, 202302 seed financing round totalling >£500k incl investor SyndicateRoom |
2023-02-27 |
| Five Alarm Bio–Zyme Communications: public relations, 202302 service existent by Zyme |
2023-02-27 |
| Lift BioSciences–Consilium: public relations, 202302 service existent by Consilium Strategic Communications |
2023-02-16 |
| Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM |
2023-02-16 |
| Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) |
2023-02-15 |
| Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma |
2023-02-15 |
| Maxion Therapeutics–BGF: investment, 202302 financing round Series A totalling £13m incl co-investor BGF |
2023-02-15 |
| Maxion Therapeutics–LifeArc: investment, 202302 financing round Series A totalling £13m incl lead investor LifeArc Ventures |
2023-02-15 |
| Maxion Therapeutics–Monograph Capital: investment, 202302 financing round Series A totalling £13m incl co-investor Monograph Capital |
2023-02-15 |
| Maxion Therapeutics–SEVERAL: investment, 202302 financing round Series A £13m led by LifeArc Ventures |
2023-02-15 |
| Cerevance–SEVERAL: investment, 202302 financing round Series B extension $51m bringing total Series B to $116m |
2023-02-13 |
| Cydar–SEVERAL: investment, 202302 financing round Series A £9.3m led by Pembroke VCT + Downing Healthcare Ventures |
2023-02-13 |
| HEL Group–Zyme Communications: public relations, 202302 service existent by Zyme |
2023-02-08 |
| Evonetix–Cambridge Consultants: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Cambridge Consultants |
2023-02-07 |
| Evonetix–Civilization Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Civilization Ventures |
2023-02-07 |
| Evonetix–DCVC: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor DCVC |
2023-02-07 |
| Evonetix–Foresite Capital: investment, 202302 financing round Series B extension totalling £20m incl existing + lead investor Foresite Capital |
2023-02-07 |
| Evonetix–Molten Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Molten Ventures |
2023-02-07 |
| Evonetix–Morningside: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Morningside |
2023-02-07 |
| Evonetix–Providence Investment: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Providence |
2023-02-07 |
| Evonetix–SEVERAL: investment, 202302 financing round Series B extension £20m bringing total Series B to £43m |
2023-02-07 |
| AstraZeneca–Capitainer: sample extraction, 202301– collab research using CapitainerCF self-sampling for clinical research with AZ R&D Gothenbur |
2023-01-30 |
| DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
| Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer |
2023-01-18 |
| Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-17 |
| Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
| Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO |
2023-01-09 |
| Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED |
2023-01-08 |
| Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners |
2023-01-05 |
| Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute |
2023-01-05 |
| Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners |
2023-01-05 |
| Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP |
2023-01-05 |
| Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED |
2022-12-22 |
| Inceptor Bio–Ori Biotech: CAGT manufacturing technology, 202212– collab early access to Ori Biotech’s fully automated CGT manufacturing platform |
2022-12-15 |
| Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs |
2022-12-14 |
| Storm Therapeutics–Cambridge Innovation Capital: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor CIC |
2022-12-14 |
| Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI |
2022-12-14 |
| Storm Therapeutics–IP Group: investment, 202212 financing round Series B totalling $30m incl existing + co-investor IP Group plc |
2022-12-14 |
| Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures |
2022-12-14 |
| Storm Therapeutics–Otsuka: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Taiho Ventures LLC |
2022-12-14 |
| Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures |
2022-12-14 |
| Storm Therapeutics–Seroba: investment, 202212 financing round Series B totalling $30m incl existing + co-investor Seroba Life Sciences |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| Storm Therapeutics–Univ Tokyo: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor UTokyo IPC |
2022-12-14 |
| BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures |
2022-12-13 |
| BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures |
2022-12-13 |
| BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health |
2022-12-13 |
| BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises |
2022-12-13 |
| BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises |
2022-12-13 |
| BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital |
2022-12-13 |
| BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures |
2022-12-13 |
| Green Bioactives–Javelin Ventures: investment, 202212 seed financing round totalling £2.6m incl lead investor Eos Advisory LLP |
2022-12-13 |
| Green Bioactives–Milltrust International: investment, 202212 seed financing round totalling £2.6m incl co-investor Green Earth Ventures Fund |
2022-12-13 |
| Green Bioactives–Regenerate Ventures: investment, 202212 seed financing round totalling £2.6m incl co-investor RV Agtech Fund |
2022-12-13 |
| Green Bioactives–Scotland (govt): investment, 202212 seed financing round totalling £2.6m incl co-investor Scottish Enterprise |
2022-12-13 |
| Green Bioactives–SEVERAL: investment, 202212 seed financing round £2.6m led by Eos Advisory LLP |
2022-12-13 |
| Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand |
2022-12-13 |
| Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share |
2022-12-12 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Genezen–Ramarketing: public relations, 202211 service existent Ramarketing is media contact |
2022-11-29 |
| Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis |
2022-11-29 |
| Rgenta Therapeutics–AstraZeneca: investment, 202211 financing round Series A totalling $52m incl new + lead investor AZ-CICC Fund |
2022-11-29 |
| Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund |
2022-11-29 |
| Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform |
2022-11-29 |
| V7–Air Street Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Air Street Capital |
2022-11-28 |
| V7–Amadeus Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Amadeus Capital Partners |
2022-11-28 |
| V7–Partech: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Partech |
2022-11-28 |
| V7–PERSON: investment, 202211 financing round Series A totalling $33m incl ML pioneers Francois Chollet + Oriol Vinyals + Jose Valim + Ashish Vaswani |
2022-11-28 |
| V7–Radical Ventures: investment, 202211 financing round Series A totalling $33m incl co-lead investor Radical Ventures |
2022-11-28 |
| V7–SEVERAL: investment, 202211 financing round Series A $33m co-led by Radical Ventures + Temasek |
2022-11-28 |
| V7–Temasek: investment, 202211 financing round Series A totalling $33m incl co-lead investor Temasek |
2022-11-28 |
| Turbine–Accel: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Accel |
2022-11-22 |
| Turbine–Day One Capital: investment, 202211 financing round Series A totalling €20m incl new + co-investor Day One Capital |
2022-11-22 |
| Turbine–Delin Ventures: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Delin Ventures |
2022-11-22 |
| Turbine–Mercia: investment, 202211 financing round Series A totalling €20m incl new + co-lead investor Mercia Asset Management |
2022-11-22 |
| Turbine–Merck (US): investment, 202211 financing round Series A totalling €20m incl new + co-lead investor MSD GHI Fund |
2022-11-22 |
| Turbine–SEVERAL: investment, 202211 financing round Series A €20m co-led by Merck GHI Fund + Mercia Asset Management |
2022-11-22 |
| Turbine–XTX Markets: investment, 202211 financing round Series A totalling €20m incl existing + co-investor XTX Ventures |
2022-11-22 |
| Accession Therapeutics–SEVERAL: investment, 202211 2nd financing round £16.6m incl iGlobe Partners + Primavera Venture Partners + Birk Venture |
2022-11-21 |
| Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures |
2022-11-17 |
| Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital |
2022-11-17 |
| Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital |
2022-11-17 |
| Sarcura–Lansdowne Partners: investment, 202211 seed plus financing round totalling €7m incl existing + co-lead investor Lansdowne Investment Co Cyprus |
2022-11-17 |
| Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube |
2022-11-17 |
| Voyager Therapeutics–Touchlight: dbDNA technology, 202211– license €na to use dbDNA technology in creation of novel capsids |
2022-11-15 |
| Sartorius–SEVERAL: credit, 202211– placement of total of €650m Schulschein loans with 3, 5, 7, 10 + 13 years maturity |
2022-11-11 |
| NRG Therapeutics–Brandon Capital: investment, 202211 financing round Series A totalling £16m incl new + co-investor Brandon Capital |
2022-11-09 |
| NRG Therapeutics–Omega Funds: investment, 202211 financing round Series A totalling £16m incl new + lead investor Omega Funds |
2022-11-09 |
| NRG Therapeutics–Parkinson’s UK: investment, 202211 financing round Series A totalling £16m incl founding + co-investor Parkinson’s Virtual Biotech |
2022-11-09 |
| NRG Therapeutics–SEVERAL: investment, 202211 financing round Series A £16m led by new investor Omega Funds |
2022-11-09 |
![[LSUK] Life-Sciences-UK.com - The UK Life Sciences Web Portal](/images/basics/lsuk-life-sciences-uk-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
